137 related articles for article (PubMed ID: 18654781)
1. A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
Tempescul A; Feuerbach J; Ianotto JC; Dalbies F; Marion V; Le Bris MJ; De Braekeleer M; Berthou C
Ann Hematol; 2009 Jan; 88(1):85-8. PubMed ID: 18654781
[No Abstract] [Full Text] [Related]
2. [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
Valiev TT; Vinogradova IuE; Chernova NG; Mar'in DS; Volkova IaK; Petrova VI; Bulanov AIu; Kalinin NN; Semenova EA; Gretsov EM; Kravchenko SK; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2006; 78(7):87-90. PubMed ID: 16944758
[No Abstract] [Full Text] [Related]
3. [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
Telek B; Batár P; Rejto L; Udvardy M
Orv Hetil; 2010 Aug; 151(31):1261-3. PubMed ID: 20656663
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Bosch F; Abrisqueta P; Villamor N; Terol MJ; González-Barca E; Ferra C; González Diaz M; Abella E; Delgado J; Carbonell F; García Marco JA; Escoda L; Ferrer S; Monzó E; González Y; Estany C; Jarque I; Salamero O; Muntañola A; Montserrat E
J Clin Oncol; 2009 Sep; 27(27):4578-84. PubMed ID: 19704063
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Tsutsumi Y; Kanamori H; Minami H; Musashi M; Fukushima A; Ehira N; Yamato H; Obara S; Ogura N; Tanaka J; Asaka M; Imamura M; Masauzi N
Ann Hematol; 2005 Apr; 84(4):269-71. PubMed ID: 15592832
[TBL] [Abstract][Full Text] [Related]
6. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
8. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
[TBL] [Abstract][Full Text] [Related]
9. Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Scaramucci L; Niscola P; Buffolino S; Bongarzoni V; Cimino G; Montanaro M
Hematol J; 2004; 5(2):186-7. PubMed ID: 15048071
[No Abstract] [Full Text] [Related]
10. Changing the way we think about chronic lymphocytic leukemia.
Lin TS; Grever MR; Byrd JC
J Clin Oncol; 2005 Jun; 23(18):4009-12. PubMed ID: 15767640
[No Abstract] [Full Text] [Related]
11. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Ahmadi T; Schuster SJ
J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
[No Abstract] [Full Text] [Related]
12. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
[No Abstract] [Full Text] [Related]
14. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
Martin-Salces M; Canales MA; de Paz R; Hernandez-Navarro F
Leuk Res; 2008 Jan; 32(1):199-200. PubMed ID: 17870157
[No Abstract] [Full Text] [Related]
15. [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Hanamura A; Hayakawa M; Naito K
Rinsho Ketsueki; 2005 Jan; 46(1):13-8. PubMed ID: 16708912
[TBL] [Abstract][Full Text] [Related]
16. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
Tse E; Chan JC; Pang A; Au WY; Leung AY; Lam CC; Kwong YL
Leukemia; 2007 Oct; 21(10):2225-6. PubMed ID: 17525720
[No Abstract] [Full Text] [Related]
18. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Candoni A; Simeone E; Tiribelli M; Malagola M; Russo D; Fanin R
Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
[No Abstract] [Full Text] [Related]
19. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
Goldaniga M; Guffanti A; Gianelli U; Magni M; Lambertenghi Deliliers G; Baldini L
Haematologica; 2004 Nov; 89(11):ECR41. PubMed ID: 15533846
[No Abstract] [Full Text] [Related]
20. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]